Pharmamarketeer

Novartis reports positive results from phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma

Novartis announced that investigational, once─daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and mometasone furoate or IND/MF) in improving trough forced expiratory

Medhc-fases-banner
Advertentie(s)